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Abstract The protein kinase C (PKC) inhibitors Ro 318220 
and GF 109203X have been used in over 350 published studies to 
investigate the physiological roles of PKC. Here we demonstrate 
that these inhibitors are not selective for PKC isoforms as was 
previously assumed. Ro 318220 inhibited MAPKAP kinase-Iß 
(also known as Rsk-2) in vitro (IC5 0 3 nM) more potently than it 
inhibited mixed PKC isoforms (IC5o 5 nM), and it also inhibited 
p70 S6 kinase (IC 5 0 15 nM). GF 109203X also potently 
inhibited MAPKAP kinase-lß (IC5 0 50 nM) and p70 S6 kinase 
(IC5 0 100 nM) with similar potency to PKC isoforms (IC5 0 
30 nM). The inhibition of MAPKAP kinase-lß, p70 S6 kinase, 
and probably other protein kinases, may explain many of the 
effects previously attributed to PKC. 
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1. Introduction 
The a, ß and y isoforms of protein kinase C (PKC, here-
after termed 'mixed P K C isoforms') are activated by the sec-
ond messenger diacylglycerol, which is generated in response 
to a variety of agonists [1]. The mixed P K C isoforms are 
thought to mediate numerous signal transduction processes 
including the control of cell growth, differentiation and ho-
meostasis. Much of the evidence implicating P K C in these 
events has been based on the use of either tumour-promoting 
phorbol esters, which are thought to activate P K C by mim-
icking diacylglycerol, and on the use of two small cell per-
meable inhibitors of P K C namely Ro 318220 [2] and 
G F 109203X [3]. These two compounds are bisindoylmalei-
mides which differ from each other in two functional groups 
and are analogues of staurosporine. They are both potent 
inhibitors of the a, ß and y isoforms, with IC 5 0 values in 
the n M range, and compete for the ATP-binding site on 
P K C [3-5]. They have been reported to be specific inhibitors 
in that two other serine/threonine-specific protein kinases, 
protein kinase A (PKA) and a calcium/calmodulin-dependent 
protein kinase(s), and several receptor protein tyrosine kinases 
were only inhibited at 1000-fold higher concentrations [2,3]. 
Since the introduction of R o 318220 and G F 109203X, these 
compounds have been used in over 350 published studies to 
implicate mixed P K C isoforms in the regulation of many cel-
lular processes. However, the validity of these findings rests 
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on the assumption that they inhibit mixed P K C isoforms se-
lectively when used in cell-based assays at low micromolar 
concentrations. Here we show that two other protein kinases, 
M A P kinase-activated protein (MAPKAP) kinase-lß (also 
known as Rsk-2) and p70 S6 kinase, which become activated 
in response to a variety of extracellular signals including phor-
bol esters, are inhibited by Ro 318220 and G F 109203X at 
concentrations similar to those which inhibit mixed P K C iso-
forms. These studies indicate that neither inhibitor is suffi-
ciently specific to implicate P K C in the regulation of a phys-
iological process, and that many of the effects ascribed to 
P K C may instead result from the inhibition of M A P K A P -
K l ß , p70 S6 kinase or other protein kinases. 
2. Materials 
Ro 318220 was a kind gift from Dr. D. Bradshaw (Roche Pharma-
ceutical Company, Welwyn Garden City, UK) and GF 109203X was 
purchased from Calbiochem (Nottingham, UK). Both inhibitors were 
dissolved in DMSO at a concentration of 50 mM and stored in ali-
quots at —20°C. Mixed PKC isoforms and histone HI, were pur-
chased from Boehringer Mannheim (Lewis, UK) and myelin basic 
protein (MBP) was from Life Technologies (Paisley, UK). MAP-
KAP-Klß [6] and MAPKAP-K2 [7] were purified from rabbit skeletal 
muscle by Dr. N. Morrice (MRC Protein Phosphorylation Unit, Dun-
dee). The p70 S6 kinase was partially purified from the livers of rats 
treated with cycloheximide [8] by Dr. S. Dale (MRC Protein Phos-
phorylation Unit, Dundee). Protein kinase Ba (also known as c-Akt 
or RAC kinase) was immunoprecipitated from IGF-1 stimulated 293 
cells overexpressing this kinase [9]. c-Rafl was obtained from Sf9 cells 
infected with bacculoviruses encoding c-Rafl, Ras and lck [10]. MAP 
kinase kinase-1 (MAPKK-1) and p42 MAP kinase were expressed in 
E. coli as glutathione S-transferase fusion proteins [11] and then acti-
vated in vitro with c-Raf and activated MAPKK-1, respectively [12]. 
All peptides used to assay protein kinases, and TTYADFIASGRTG-
RRNAIHD (the specific peptide inhibitor of cyclic AMP dependent 
protein kinase-PKI) were synthesised by Mr. F.B. Caudwell at Dun-
dee on an Applied Biosystems 431A peptide syntheser. Their purity 
was ( > 95%) and their concentrations were determined by quantita-
tive amino acid analysis. 
2.1. Protein kinase assays 
All protein kinases except c-Raf and MAPKK-1 were assayed as 
follows: a 40 ul assay mix was prepared containing protein kinase 
(0.2 U/ml) in 50 mM Tris-HCl, pH 7.5, 0.1 mM EGTA, 0.1% (by vol) 
2-mercaptoethanol, 2.5 uM PKI, protein kinase substrate (30 uM), 
and the indicated concentration of Ro 318220 or GF 109203X. After 
incubation on ice for 10 min the reaction was started by the addition 
of 10 ul of 50 mM magnesium acetate and 0.5 mM [y!2P]ATP (100-
200 cpm/pmol). For the assay of mixed isoforms of PKC, 20 uM 
diacylglycerol, 0.5 mM CaCl2, and 100 uM phosphatidylserine were 
also present in the incubations. The assays were carried out for 15 min 
at 30°C, then terminated and analysed as described [11]. One unit of 
activity was that amount of enzyme that catalysed the phosphoryla-
tion of 1 nmol of substrate in 1 min. The final concentration of 
DMSO in each assay was 1% (by vol). This concentration of 
DMSO does not inhibit any of these enzymes. Mixed isoforms of 
PKC were assayed using histone HI as substrate, while MAPKAP-
Klß and p70 S6 kinase were assayed using the peptide KKRNRTL-
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SVA [8]. PKB was assayed with the peptide GRPRTSSFAEG [9] and 
MAPKAP-K2 was assayed with the peptide KKLNRTLSVA [13]. 
p42 MAP kinase was assayed using MBP, and MAPKK-1, and c-
Rafl were assayed as described in [11]. 
3. Results 
3.1. Effect of Ro 318220 and GF 109203X on protein kinases 
activated by growth factors, cytokines and cellular stresses 
As reported previously [2], the mixed isoforms of PKC were 
potently inhibited by Ro 318220, with an IC50 of 5 nM in our 
assay (Fig. 1A). In contrast, a number of protein kinases 
activated by growth factors (c-Rafl, MAPKK-1, p42 MAP 
kinase) and one protein kinase that is activated by cellular 
stresses and proinflammatory cytokines (MAPKAP-K2) 
were not inhibited significantly by Ro 318022 in vitro (Fig. 
1A). PKBoc, an enzyme that is activated in response to insulin 
and growth factors, was inhibited by Ro 318220 (IC50 of 
1 uM, Fig. IB) similar to the IC50 for PKA. However, to 
our surprise, MAPKAP-Klß an enzyme which lies immedi-
ately downstream of p42 and p44 MAP kinases and which is 
activated in response to every agonist that stimulates this 
pathway, was inhibited by Ro 318220 even more potently 
than the mixed PKC isoforms (IC50 = 3 nM, Fig. IB). The 
p70 S6 kinase, which lies on a distinct growth factor-stimul-
ated signalling pathway from MAPKAP-Klß, was also po-
tently inhibited by Ro 318220 (IC50 = 15 nM, Fig. IB). 
Similar results were obtained using GF 109203X instead of 
Ro 318220. As reported previously [3], GF 109203X inhibited 
the mixed isoforms of PKC (IC50 = 30 nM) without inhibiting 
PKBa (Fig. 2) or c-Raf, MAPKK-1 and p42 MAP kinase 
(data not shown). However MAPKAP-Klß and p70 S6 ki-
nase were potently inhibited by this compound with IC5o val-
ues of 50 nM and 100 nM, respectively (Fig. 2). 
4. Discussion 
In this communication we have shown that Ro 318220 and 
GF 109203X are not selective inhibitors of the mixed PKC 
isoforms. We demonstrated that both MAPKAP-Klß and 
p70 S6 kinase are inhibited with similar potency by 
Ro 318220 and GF 109203X (Figs. 1 and 2). The amino 
acid sequence of the catalytic domain of p70 S6 kinase and 
the N-terminal kinase domain of MAPKAP-Klß are both 
40% identical to the catalytic domain of PKCoc. This degree 
of identity is similar to that between the catalytic domains of 
PKCce and PKA or between PKCcc and PKBa; PKA and 
PKBa are inhibited by Ro 318220 at 100-1000-fold higher 
concentration than mixed PKC isoforms. These findings em-
phasise the danger in assuming that any given kinase inhibitor 
is specific, unless it has been tested against a substantial num-
ber of other kinases, and not simply those kinases which are 
most closely related in structure. 
MAPKAP-Klß and p70 S6 kinase both lie on distinct sig-
nalling pathways that are activated in response to growth 
factors and signals that also activate mixed PKC isoforms. 
Thus the blockade of a growth-factor mediated effect by 
Ro 318220 or GF 109203X may be explained by inhibition 
of MAPKAP-Klß and/or p70 S6 kinase, even in situations 
where the effect of the growth factor is mimicked by phorbol 
esters. 
PKC is known to be stimulated during antigen-induced T-
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Fig. 1. Effect of Ro 318022 on the activity of a variety of agonist 
regulated protein kinases. A: Effect of Ro 318220 on mixed PKC 
isoforms (o) and on c-Raf, MAPKK-1, p42 MAP kinase, and 
MAPKAP-K2 (•). These 4 kinases were all affected similarly by 
Ro 318220. B: Effect of Ro 318022 on mixed PKC isoforms (o), 
MAPKAP-Klß ( A ) , p70 S6 kinase (•) and PKB ( A ) . The results 
are presented relative to control incubations in which the inhibitor 
was omitted and are shown as the average of 3 experiments with 
each determination carried out in triplicate. The error for each data 
point is < 5% unless otherwise indicated. 
cell activation and Ro 318220, GF 109203X and similar bisin-
doylmaleimide derivatives have been shown to suppress anti-
gen-driven T-cell proliferation in cultured cells and in vivo, 
raising interest in the potential use of PKC inhibitors as im-
munosuppressants [5,14]. However, since the immunosuppres-
sant drug rapamycin is a potent and specific inhibitor of the 
activation of p70 S6 kinase [15], it is possible that the immu-
nosuppressant effects of Ro 318220 and GF 109203X result 
from inhibition of p70 S6 kinase rather than PKC. The ther-
apeutic use of drugs related to Ro 318220 and GF 109203X 
will also need be evaluated very carefully in the light of the 
recent discovery of the cause of Coffin-Lowry syndrome [16]. 
This genetic disease, which leads to progressive skeletal defor-
mation and severe mental retardation results from the muta-
tional-inactivation of the same MAPKAP-K1 isoform (MAP-
KAP-Klß) used in this study [16]. 
It will also be important for investigators who have exam-
ined the effects of Ro 318220 and GF 109203X on any cellu-
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Fig. 2. Effect of GF 102203X on the activity variety of agonist 
regulated protein kinases. Effect of GF 109203X on mixed PKC iso-
forms (o), MAPKAP-Klß ( A ) , p70 S6 kinase (•), and PKBcc ( A ) . 
The results are presented relative to control incubations in which 
the inhibitor was omitted and are shown as the average of 2 experi-
ments with each determination carried out in triplicate. The error 
for each data point is < 5% SEM. 
lar process to check whether that process is also blocked by 
rapamycin [15] or by PD 98059 [17]. The last mentioned drug, 
which is an extremely specific inhibitor of the activation of 
MAPKK-1, prevents the activation of p42 and p44 MAP ki-
nases and hence the activation of MAPKAP-K1 [17]. 
Evidence that Ro 318220 may not be a specific inhibitor of 
mixed PKC isoforms in cell based assays was recently re-
ported by others [18]. In these studies Ro 318220 prevented 
the induction of MAP kinase phosphatase-1 and the tran-
scription factor c-Fos by growth factors, and stimulated acti-
vation of the stress-activated protein kinase JNK in the ab-
sence of growth factors, even after depletion of mixed PKC 
isoforms by prolonged treatment with phorbol esters. The 
suppression of c-Fos induction by Ro 318220 may result 
from the inhibition of MAPKAP-Klß since this enzyme has 
been implicated in the nerve growth factor-stimulated induc-
tion of c-Fos in PC12 cells [19]. Inhibition of MAPKAP-Klß 
might also underlie the suppression of MAP kinase phospha-
tase-1 induction by growth factors, since PD 98059 prevents 
the induction of this phosphatase by IGF-1 in L6 myotubes 
(T. Lewis, S. Keyse, and D. Alessi, unpublished work). Belt-
man et al. [18] reported that GF 109203X, when used at a 
concentration of 2.5 uM, did not mimic the effects of 
Ro 318220 used at a concentration of 5 u.M. This is also 
consistent with the possible involvement of MAPKAP-Klß 
which is inhibited by 15-fold less potently by GF 109203X 
than by Ro 318220 (Figs. 1 and 2). 
In summary, Ro 318220 potently inhibits at least three 
types of protein kinase (and probably more). To my knowl-
123 
edge the only three inhibitors of serine/threonine-specific pro-
tein kinases which have so far survived rigorous studies of 
their specificity, both in vitro and in cell-based systems, are 
the p38/RK MAP kinase inhibitor SB 203580 [20], the inhib-
itor of MAPKK-1 activation PD 98059 [17], and rapamycin 
[15]. 
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